

The Journal of Rheumatology

VOLUME 38: NO. 7

jrheum.org

JULY 2011

Editorials

- All That Glitters Is Not Gold – Standardizing Diagnosis in Rheumatoid Arthritis Studies** *K.P. Liao, V. Bykerk* 1223
- Who's Holding up the Queue? Delay in Treatment of Rheumatoid Arthritis** *J.E. Homik* 1225
- Rehabilitation for Ankylosing Spondylitis in the Era of Biologics: Any Room Left for This Treatment?** *E. Lubrano, S. D'Angelo, A. Spadaro, C. Palazzi, I. Olivieri* 1228
- Should Clinicians Start Measuring Flow Mediated Dilation Response in Patients with Systemic Lupus Erythematosus?** *C.S. Lau* 1231

Review

- Challenges in Diagnosing Latent TB Infection in Patients Treated with TNF Antagonists** *E.C. Keystone, K.A. Papp, W. Wobeser* 1234

Articles

- Lymphotoxin- α 252 A>G Polymorphism: A Link Between Disease Susceptibility and Dyslipidemia in RA?** *M.J. Santos, D. Fernandes, J. Caetano-Lopes, et al* 1244
- Diagnostic Accuracy of ACR/EULAR 2010 Criteria for RA in a 2-Year Cohort** *S. Varache, D. Cornec, J. Morvan, et al* 1250
- Incidence and Risk Factors for Serious Infection in Patients with RA Treated with TNF Inhibitors: A Report from the Registry of Japanese RA Patients for Longterm Safety** *Y. Komano, M. Tanaka, T. Nanki, et al, for the REAL Study Group* 1258
- A Comparison Between IgG- and IgA-class Antibodies to CCP and to Modified Citrullinated Vimentin in Early RA and Very Early Arthritis** *A. Svård, A. Kastbom, M.K. Söderlin, Å. Reckner-Olsson, T. Skogh* 1265
- Persistence with Anti-TNF Therapies in Patients with RA: Observations from the RADIUS Registry** *J.A. Markenson, A. Gibofsky, W.R. Palmer, et al* 1273
- Time to Treatment for New Patients with RA in a Major Metropolitan City** *S. Jamal, S.M.H. Alibhai, E.M. Badley, C. Bombardier* 1282
- Prognostic Indicators of Hospitalized Patients with SLE: A Large Retrospective Multicenter Study in China** *X. Feng, Y. Zou, W. Pan, et al* 1289

- Endothelium-dependent But Not Endothelium-independent Flow-mediated Dilation Is Significantly Reduced in Patients with SLE without Vascular Events: A Metaanalysis and Metaregression** *A. Mak, Y. Liu, R.C-M Ho* 1296
- Longterm Followup After Tapering MMF During Maintenance Treatment for Proliferative Lupus Nephritis** *K. Laskari, A.G. Tzioufas, A. Antoniou, H.M. Moutsopoulos* 1304
- Quantitative Data for Care of Patients with SLE in Usual Clinical Settings: A Patient Multidimensional HAQ and Physician Estimate of Noninflammatory Symptoms** *A.D. Askanase, I. Castrejón, T. Pincus* 1309
- Late-age Onset SSc** *R.L. Manno, F.M. Wigley, A.C. Gelber, L.K. Hummers* 1317
- Expert Agreement on EULAR/EUSTAR Recommendations for the Management of SSc** *K.M. Walker, J. Pope, on behalf of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group* 1326
- Malignancies in Italian Patients with SSc Positive for Anti-RNA Polymerase III Antibodies** *P. Airo', A. Ceribelli, I. Cavazzana, M. Taraborelli, S. Zingarelli, F. Franceschini* 1329
- Rehabilitation Treatment in Patients with AS Stabilized with TNF Inhibitor Therapy. A Randomized Controlled Trial** *S. Masiero, L. Bonaldo, M. Pigatto, A. Lo Nigro, R. Ramonda, L. Punzi* 1335
- The SPARCC Registry for SpA** *D.D. Gladman, P. Rahman, R.J. Cook, et al* 1343
- Resolution of Inflammation Following Treatment of AS Is Associated with New Bone Formation** *S.J. Pedersen, P. Chiowchanwisawakit, R.G.W. Lambert, M. Østergaard, W.P. Maksymowych* 1349
- Effectiveness and Safety of Etanercept in Patients with PsA in a Canadian Clinical Practice Setting: The REPARÉ Trial** *D.D. Gladman, C. Bombardier, C. Thorne, et al* 1355
- High Prevalence of Subclinical Left Ventricular Dysfunction in Patients with PsA** *Q. Shang, L-S. Tam, G.W-K. Yip, et al* 1363
- Prevalence of Thyroid Autoimmunity in Patients with SpA** *R. Peluso, G.A. Lupoli, A. Del Puente, et al* 1371
- Candidate Genes in Patients with Autoinflammatory Syndrome Resembling TNF Receptor-associated Periodic Syndrome Without Mutations in the *TNFRSF1A* Gene** *S. Borghini, M. Fiore, M. Di Duca, et al* 1378

 Free online via JRheum Full Release option

Febuxostat in Gout: Serum Urate Response in Uric Acid Overproducers and Underexcretors *D.S. Goldfarb, P.A. MacDonald, B. Hunt, L. Gunawardhana* 1385

Consistency of Knee Pain and Risk of Knee Replacement: The Multicenter OA Study
B.L. Wise, D.T. Felson, M. Clancy, et al. 1390

Bisphosphonate-associated Osteonecrosis of the Jaw in Ontario: A Survey of Oral and Maxillofacial Surgeons
A.A. Khan, L.P. Rios, G.K.B. Sandor, et al. 1396

Longterm Therapeutic Response to Milnacipran Treatment for FM. A European 1-Year Extension Study Following a 3-Month Study *J.C. Branco, P. Cherin, A. Montagne, A. Bouroubi, on behalf of the Multinational Coordinator Study Group.* 1403

Specialized Rheumatology Nurse Substitutes for Rheumatologists in the Diagnostic Process of FM: A Cost-Consequence Analysis and RCT
M.E. Kroese, J.L. Severens, G.J. Schulpen, M.C. Bessems, F.J. Nijhuis, R.B. Landewé 1413

Pediatric Rheumatology

Heterotopic Ossification of the TMJ in JIA
S. Ringold, M. Thapa, E.A. Shaw, C.A. Wallace 1423

MBL Expression Genotype in Pediatric-onset SLE: Associations with Susceptibility to Renal Disease and Protection Against Infections *Y-C. Tsai, K-W. Yeh, T-C. Yao, Y-L. Huang, M-L. Kuo, J-L. Huang.* 1429

Safety and Efficacy of Rituximab in Severe Juvenile DM: Results from 9 Patients from the French Autoimmunity and Rituximab Registry
B. Bader-Meunier, H. Decaluwe, C. Barnerias, et al, for the Club Rhumatismes et Inflammation 1436

Development of IBD in Patients with JIA Treated with Etanercept
T.D. van Dijken, S.J. Vastert, V.M. Gerloni, et al. 1441

Images in Rheumatology

Fluorescence Optical Imaging of Juvenile Arthritis
S.G. Werner, H-E. Langer, G. Horneff 1447

OMERACT 10 10th International Consensus Conference on Outcome Measures in Rheumatology Kota Kinabalu, Borneo - May 4-8, 2010

Introduction 1448

Disease-specific Outcomes

Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10 *J.A. Singh, W.J. Taylor, L.S. Simon, et al.* 1452

Tophus Measurement as an Outcome Measure for Clinical Trials of Chronic Gout: Progress and Research Priorities
N. Dalbeth, F.M. McQueen, J.A. Singh, et al. 1458

Serum Urate in Chronic Gout — Will It Be the First Validated Soluble Biomarker in Rheumatology?
L.K. Stamp, P.P. Khanna, N. Dalbeth, et al. 1462

Bringing It All Together: A Novel Approach to the Development of Response Criteria for Chronic Gout Clinical Trials
W.J. Taylor, J.A. Singh, K.G. Saag, et al. 1467

Development of Outcome Measures for Large-vessel Vasculitis for Use in Clinical Trials: Opportunities, Challenges, and Research Agenda
H. Direskeneli, S.Z. Aydin, T.A. Kermani, et al. 1471

The OMERACT Core Set of Outcome Measures for Use in Clinical Trials of ANCA-associated Vasculitis
P.A. Merkel, S.Z. Aydin, M. Boers, et al. 1480

Toward Development of a FM Responder Index and Disease Activity Score: OMERACT Module Update
P.J. Mease, D.J. Clauw, R. Christensen, et al, and the OMERACT Fibromyalgia Working Group. 1487

Development of a Disease Severity and Responder Index for PsA — Report of the OMERACT 10 PsA SIG
L.C. Coates, A. Mumtaz, P.S. Helliwell, et al. 1496

Endorsement of Definitions of Disease Activity States and Improvement Scores for the AS Disease Activity Score: Results from OMERACT 10 *P.M.M.C. Machado, R.B.M. Landewé, D.M. van der Heijde.* 1502

Early Postoperative Mortality Following Joint Arthroplasty: A Systematic Review *J.A. Singh, J. Kundukulam, D.L. Riddle, V. Strand, P. Tugwell* 1507

Developing Disease Activity and Response Criteria in CTD-related ILD *L.A. Saketkoo, E.L. Matteson, K.K. Brown, J.R. Seibold, V. Strand; for the Connective Tissue Disease-related Interstitial Lung Disease Special Interest Group.* 1514

Correspondence

Where in the World is Oral Triamcinolone? *L. Roger.* 1519

Reply *R. Alten.* 1519

Lupus Related Longitudinal Myelitis
D.M. Wingerchuk, B.G. Weinshenker. 1520

Reply *P. Zotos.* 1521

Coexistent WG and Goodpasture's Disease: What Is the Mechanism? *J.I. Shin, S.J. Park, J.H. Kim.* 1521

Who Discovered the ESR? *A. Grzybowski, J.J. Sak.* 1521

Reply *E.L. Matteson, C.S. Crowson.* 1523

Letters

Serum Levels of HMGB1 in Postmenopausal Patients with RA: Associations with Proinflammatory Cytokines, Acute-phase Reactants, and Clinical Disease Characteristics
R. Pullerits, V. Urbonaviciute, R.E. Voll, H. Forsblad-D'Elia, H. Carlsten. 1523

Acute Presentation of Tophaceous Myelopathy
E. Levin, K. Hurth, R. Joshi, R. Brasington. 1525

AS Refractory to TNF Blockade Responds to Tocilizumab
J-D. Cohen, R. Ferreira, C. Jorgensen. 1527

Positive C-ANCA with PR3 Specificity Glomerulonephritis in a Patient with Subacute Bacterial Endocarditis
M. Uh, I.A. McCormick, J.T. Kelsall. 1528

Primary Aldosteronism Simulating Polymyositis
Y-C. Tang, S-K. Wang, W-L. Yuan. 1529

Corrections

Intraarticular Botulinum Toxin A for Refractory Painful Total Knee Arthroplasty: A Randomized Controlled Trial
J.A. Singh, M.L. Mahowald, S. Noorbaloochi. 1534

Anti-Fibrillar Antibody in African American Patients with Systemic Sclerosis: Immunogenetics, Clinical Features, and Survival Analysis *S. Sharif, M.J. Fritzler, M.D. Mayes, et al.* . . 1534

Meetings in Rheumatology xi